A Study of Plasma miR-23a Expression in Vitiligo Patients | ||||
| Suez Canal University Medical Journal | ||||
| Article 1, Volume 26, Issue 1, January 2023, Page 1-10 PDF (442.84 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/scumj.2023.283958 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Doaa O. Salman; Eman A. Mohammed; Eman A. Toraih; Alia Ellawindy 
| ||||
| Medical Genetics Unit, Department of Histology & Cell Biology, Faculty of Medicine, Suez Canal University, Egypt | ||||
| Abstract | ||||
| Background: Vitiligo is a chronic autoimmune skin depigmentation disorder with multifactorial causation, involving genetic susceptibility, immunological events, and environmental triggers. The exact molecular mechanisms of vitiligo development and progression are poorly understood. Recent studies reported microRNAs as promising biomarkers for disease detection and molecular targets for future treatment. Aim: Evaluating the expression level of circulating miR-23a in vitiligo patients and its association with the clinical features of vitiligo. Subjects and Methods: This is a case-control study comprising 50 vitiligo patients and 44 healthy controls. Plasma miR-23a expression levels were estimated by quantitative real-time PCR. Bioinformatic analysis for the miR-23a gene was performed. Results: Vitiligo patients displayed significantly lower circulating miR-23a expression levels compared to healthy controls. There was a significant negative correlation between miR-23a fold change and Vitiligo Area Severity Index (p < /em>= 0.003). Plasma miR-23a levels discriminated between vitiligo patients and controls with 60 % specificity and 64% sensitivity at the optimal cut-off value of 0.23 and likelihood ratio 1.61 (AUC=0.67). Conclusion: miR-23a along with its putative target genes could play a role in vitiligo pathogenesis. | ||||
| Keywords | ||||
| MicroRNA; Autoimmune; Vitiligo; Skin | ||||
|
Statistics Article View: 228 PDF Download: 385 |
||||
